Developing Prediction Models for COVID-19 Outcomes: A Valuable Tool for Resource-Limited Hospitals.
ANC
CRP
risk profiling
unfavourable outcome
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
05
2023
accepted:
08
07
2023
medline:
25
7
2023
pubmed:
25
7
2023
entrez:
25
7
2023
Statut:
epublish
Résumé
Coronavirus disease is a global pandemic with millions of confirmed cases and hundreds of thousands of deaths worldwide that continues to create a significant burden on the healthcare systems. The aim of this study was to determine the patient clinical and paraclinical profiles that associate with COVID-19 unfavourable outcome and generate a prediction model that could separate between high-risk and low-risk groups. The present study is a multivariate observational retrospective study. A total of 483 patients, residents of the municipality of Timișoara, the biggest city in the Western Region of Romania, were included in the study group that was further divided into 3 sub-groups in accordance with the disease severity form. Increased age (cOR=1.09, 95% CI: 1.06-1.11, p<0.001), cardiovascular diseases (cOR=3.37, 95% CI: 1.96-6.08, p<0.001), renal disease (cOR=4.26, 95% CI: 2.13-8.52, p<0.001), and neurological disorder (cOR=5.46, 95% CI: 2.71-11.01, p<0.001) were all independently significantly correlated with an unfavourable outcome in the study group. The severe form increases the risk of an unfavourable outcome 19.59 times (95% CI: 11.57-34.10, p<0.001), while older age remains an independent risk factor even when disease severity is included in the statistical model. An unfavourable outcome was positively associated with increased values for the following paraclinical parameters: white blood count (WBC; cOR=1.10, 95% CI: 1.05-1.15, p<0.001), absolute neutrophil count (ANC; cOR=1.15, 95% CI: 1.09-1.21, p<0.001) and C-reactive protein (CRP; cOR=1.007, 95% CI: 1.004-1.009, p<0.001). The best prediction model including age, ANC and CRP achieved a receiver operating characteristic (ROC) curve with the area under the curve (AUC) = 0.845 (95% CI: 0.813-0.877, p<0.001); cut-off value = 0.12; sensitivity = 72.3%; specificity = 83.9%. This model and risk profiling may contribute to a more precise allocation of limited healthcare resources in a clinical setup and can guide the development of strategies for disease management.
Identifiants
pubmed: 37489130
doi: 10.2147/IJGM.S419206
pii: 419206
pmc: PMC10363379
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3053-3065Informations de copyright
© 2023 Popescu et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Clin Med. 2022 Nov 16;11(22):
pubmed: 36431254
Front Immunol. 2022 Nov 14;13:1040024
pubmed: 36451818
Turk Pediatri Ars. 2020 Dec 16;55(4):335-336
pubmed: 33414649
J Osteopath Med. 2021 Sep 30;121(12):869-873
pubmed: 34592071
Front Immunol. 2022 Jun 01;13:864387
pubmed: 35720378
Clin Chim Acta. 2020 Oct;509:235-243
pubmed: 32533986
Acad Emerg Med. 2022 Feb;29(2):206-216
pubmed: 35064988
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
BMJ Glob Health. 2021 Dec;6(12):
pubmed: 34916273
QJM. 2020 Dec 1;113(12):876-882
pubmed: 32790836
BMC Infect Dis. 2021 Jun 14;21(1):574
pubmed: 34126954
Invest Radiol. 2020 Jun;55(6):327-331
pubmed: 32118615
PLoS One. 2020 Nov 5;15(11):e0241824
pubmed: 33152008
J Bras Nefrol. 2021 Jul-Sep;43(3):383-399
pubmed: 33836039
Acad Emerg Med. 2020 Aug;27(8):653-670
pubmed: 32542934
Med. 2021 Apr 09;2(4):435-447.e4
pubmed: 33521746
Trop Dis Travel Med Vaccines. 2020 Aug 28;6:16
pubmed: 32868984
Diagnostics (Basel). 2021 Mar 26;11(4):
pubmed: 33810534
Front Neurol. 2020 Jul 07;11:781
pubmed: 32733373
J Glob Health. 2020 Dec;10(2):020510
pubmed: 33110593
Emerg Infect Dis. 2020 Aug;26(8):1839-1841
pubmed: 32384045
Int J Clin Pract. 2021 Oct;75(10):e14571
pubmed: 34170611
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855
Clin J Am Soc Nephrol. 2021 May 8;16(5):785-786
pubmed: 33558255
Rev Med Virol. 2021 Nov;31(6):e2221
pubmed: 34773448